|
| 35705026 | Characterization of the Immune Microenvironment in Inflammatory Breast Cancer Using Multiplex Immunofluorescence. | Pathobiology | 2023 |
| 35144966 | Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study. | Clin Cancer Res | 2022 |
| 35608580 | Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial. | JAMA | 2022 |
| 35526835 | Discordance between Immunohistochemistry and Erb-B2 Receptor Tyrosine Kinase 2 mRNA to Determine Human Epidermal Growth Factor Receptor 2 Low Status for Breast Cancer. | J Mol Diagn | 2022 |
| 36519303 | Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT). | Clin Cancer Res | 2022 |
| 36527133 | Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study. | Breast Cancer Res | 2022 |
| 36044833 | Eribulin Treatment for Patients with Metastatic Breast Cancer: The UK Experience - A Multicenter Retrospective Study. | Oncology | 2022 |
| 32723485 | Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK. | Clin Oncol (R Coll Radiol) | 2021 |
| 33527137 | The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32. | J Natl Cancer Inst | 2021 |
| 34485814 | Cancer Antigen 15-3/Mucin 1â¿¿Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo. | JNCI Cancer Spectr | 2021 |
| 34103538 | Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial. | NPJ Breast Cancer | 2021 |
| 34238931 | Comparative survival analysis of multiparametric tests-when molecular tests disagree-A TEAM Pathology study. | NPJ Breast Cancer | 2021 |
| 31358346 | The Breast Cancer Trainees Research Collaborative Group: A New Multidisciplinary Network to Facilitate Breast Cancer Research. | Clin Oncol (R Coll Radiol) | 2020 |
| 32089356 | Strategies to Improve Recruitment to a De-escalation Trial: A Mixed-Methods Study of the OPTIMA Prelim Trial in Early Breast Cancer. | Clin Oncol (R Coll Radiol) | 2020 |
| 31785830 | Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial. | Radiother Oncol | 2020 |
| 31836609 | Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER<sup>+</sup> Invasive Breast Cancer (STAKT). | Clin Cancer Res | 2020 |
| 32919527 | Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. | Lancet Oncol | 2020 |
| 32880572 | Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. | Health Technol Assess | 2020 |
| 32706636 | Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials. | J Clin Oncol | 2020 |
| 32129471 | The CD151-midkine pathway regulates the immune microenvironment in inflammatory breast cancer. | J Pathol | 2020 |
| 30913528 | Valuing the health states associated with breast cancer screening programmes: A systematic review of economic measures. | Soc Sci Med | 2019 |
| 35100692 | Identification of Distinct Prognostic Groups: Implications for Patient Selection to Targeted Therapies Among Anti-Endocrine Therapy-Resistant Early Breast Cancers. | JCO Precis Oncol | 2019 |
| 31160130 | The SMALL Trial: A Big Change for Small Breast Cancers. | Clin Oncol (R Coll Radiol) | 2019 |
| 31160077 | Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab. | Int J Cardiol | 2019 |
| 29721054 | International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. | J Cancer | 2018 |
| 29917140 | Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial. | J Natl Cancer Inst | 2018 |
| 29885375 | Impact of age on breast cancer mortality and competing causes of death at 10 years follow-up in the adjuvant TEAM trial. | Eur J Cancer | 2018 |
| 30420699 | Pathway-based subnetworks enable cross-disease biomarker discovery. | Nat Commun | 2018 |
| 30278369 | The presentation, management and outcome of inflammatory breast cancer cases in the UK: Data from a multi-centre retrospective review. | Breast | 2018 |
| 29470143 | Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data. | J Clin Oncol | 2018 |
| 28732650 | Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial. | Lancet Oncol | 2017 |
| 28459938 | Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial. | Ann Oncol | 2017 |
| 28479233 | Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. | Lancet Oncol | 2017 |
| 28494403 | HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. | Eur J Cancer | 2017 |
| 28441617 | The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value? | Breast | 2017 |
| 29185098 | Confusion Over Differences in Registration and Randomization Criteria for the LORIS (Low-Risk DCIS) Trial. | Ann Surg Oncol | 2017 |
| 28649643 | Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine. | NPJ Breast Cancer | 2017 |
| 28766204 | Nonoperative Management for Invasive Breast Cancer After Neoadjuvant Systemic Therapy: Conceptual Basis and Fundamental International Feasibility Clinical Trials. | Ann Surg Oncol | 2017 |
| 28548129 | Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial. | Mod Pathol | 2017 |
| 27002934 | Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. | Br J Cancer | 2016 |
| 27632243 | Comparison of quadrant-specific breast cancer incidence trends in the United States and England between 1975 and 2013. | Cancer Epidemiol | 2016 |
| 27228289 | Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. | Br J Cancer | 2016 |
| 27131315 | Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study. | Oncol Res | 2016 |
| 27130929 | Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others. | J Natl Cancer Inst | 2016 |
| 27129177 | Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen. | Oncotarget | 2016 |
| 27020141 | Viewpoint: Availability of oestrogen receptor and HER2 status for the breast multidisciplinary meeting discussion; time to get it right. | Eur J Surg Oncol | 2016 |
| 26717057 | Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial. | Arch Pathol Lab Med | 2016 |
| 26827691 | Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review. | Cancer Treat Rev | 2016 |
| 25445552 | The LORIS Trial: Addressing overtreatment of ductal carcinoma in situ. | Clin Oncol (R Coll Radiol) | 2015 |
| 26296293 | Addressing overtreatment of screen detected DCIS; the LORIS trial. | Eur J Cancer | 2015 |